Bio-Techne Corporation reported earnings results for the third quarter and nine months ended March 31, 2026. For the third quarter, the company reported sales was USD 311.42 million compared to USD 316.18 million a year ago. Net income was USD 51.05 million compared to USD 22.59 million a year ago. Basic earnings per share from continuing operations was USD 0.33 compared to USD 0.14 a year ago. Diluted earnings per share from continuing operations was USD 0.32 compared to USD 0.14 a year ago.
For the nine months, sales was USD 893.85 million compared to USD 902.67 million a year ago. Net income was USD 127.24 million compared to USD 91.08 million a year ago. Basic earnings per share from continuing operations was USD 0.82 compared to USD 0.58 a year ago. Diluted earnings per share from continuing operations was USD 0.81 compared to USD 0.57 a year ago.
Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows:
- biological and chemical reagents and analysis tools (71.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.;
- diagnostic and genomics products (28.4%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. ;
- other (0.3%).
Net sales are distributed geographically as follows: the United States (56%), the United Kingdom (4.5%), Europe/Middle East/Africa (21.8%), China (8.3%), Asia/Pacific (6.3%) and other (3.1%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
